JP2021502362A5 - - Google Patents

Download PDF

Info

Publication number
JP2021502362A5
JP2021502362A5 JP2020524855A JP2020524855A JP2021502362A5 JP 2021502362 A5 JP2021502362 A5 JP 2021502362A5 JP 2020524855 A JP2020524855 A JP 2020524855A JP 2020524855 A JP2020524855 A JP 2020524855A JP 2021502362 A5 JP2021502362 A5 JP 2021502362A5
Authority
JP
Japan
Prior art keywords
patent document
international publication
international
document
publication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020524855A
Other languages
English (en)
Japanese (ja)
Other versions
JP7220712B2 (ja
JP2021502362A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/059906 external-priority patent/WO2019094650A1/en
Publication of JP2021502362A publication Critical patent/JP2021502362A/ja
Publication of JP2021502362A5 publication Critical patent/JP2021502362A5/ja
Application granted granted Critical
Publication of JP7220712B2 publication Critical patent/JP7220712B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020524855A 2017-11-08 2018-11-08 フルベストラント製剤とその使用方法 Active JP7220712B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762583403P 2017-11-08 2017-11-08
US62/583,403 2017-11-08
PCT/US2018/059906 WO2019094650A1 (en) 2017-11-08 2018-11-08 Fulvestrant formulations and methods of their use

Publications (3)

Publication Number Publication Date
JP2021502362A JP2021502362A (ja) 2021-01-28
JP2021502362A5 true JP2021502362A5 (https=) 2021-09-24
JP7220712B2 JP7220712B2 (ja) 2023-02-10

Family

ID=64650494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020524855A Active JP7220712B2 (ja) 2017-11-08 2018-11-08 フルベストラント製剤とその使用方法

Country Status (15)

Country Link
US (1) US12186427B2 (https=)
EP (1) EP3706719A1 (https=)
JP (1) JP7220712B2 (https=)
KR (1) KR102670293B1 (https=)
CN (1) CN111479556B (https=)
AU (1) AU2018366212B2 (https=)
BR (1) BR112020009141A2 (https=)
CO (1) CO2020006951A2 (https=)
IL (1) IL274433B2 (https=)
MA (1) MA50570A (https=)
MX (2) MX2020004792A (https=)
MY (1) MY204442A (https=)
UA (1) UA128158C2 (https=)
WO (1) WO2019094650A1 (https=)
ZA (1) ZA202002897B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4074304A4 (en) * 2019-12-11 2024-01-10 Shanghai Bocimed Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION OF FULVESTRANT, PREPARATION METHOD AND APPLICATION THEREOF
CN120284882A (zh) * 2020-12-10 2025-07-11 上海云晟研新生物科技有限公司 氟维司群药物组合物、其制备方法及应用
JP2024545690A (ja) * 2021-12-20 2024-12-10 サムヤン、ホールディングス、コーポレーション 溶解度が改善されたフルベストラントの医薬組成物及びその製造方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US6495534B2 (en) 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
PL367624A1 (en) 2001-07-07 2005-03-07 Astrazeneca Ab Pharmaceutical formulation for the intramuscular administration of fulvestrant
CA2575906C (en) 2004-08-04 2014-04-15 Camurus Ab Compositions forming non-lamellar dispersions
JP2006089386A (ja) * 2004-09-21 2006-04-06 Nippon Tenganyaku Kenkyusho:Kk ステロイドまたはステロイド誘導体を含有する懸濁性医薬組成物
CN1857217A (zh) * 2006-03-28 2006-11-08 济南康泉医药科技有限公司 一种含雌激素受体拮抗剂的抗癌缓释注射剂
CN101244029A (zh) * 2006-03-28 2008-08-20 济南康泉医药科技有限公司 含雌激素受体拮抗剂的抗癌缓释注射剂
JP2011514349A (ja) * 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
CN101525364B (zh) 2008-03-07 2012-12-12 杭州九源基因工程有限公司 一种氟维司群的晶型及其制备方法
WO2011022861A1 (zh) 2009-08-31 2011-03-03 西安力邦医药科技有限责任公司 氟维司群纳米球/微球及其制备方法和用途
WO2011011978A1 (zh) * 2009-07-31 2011-02-03 西安力邦医药科技有限责任公司 微球药物载体、其制备方法、组合物及应用
CN103221052A (zh) 2010-09-16 2013-07-24 施摩达生物技术有限公司 氟维司群组合物及使用方法
EP2711010B1 (en) 2011-05-20 2018-10-31 Capital, Business Y Gestión De Finanzas, S.L Pharmaceutical composition
CA2869377C (en) * 2012-04-09 2022-11-08 Scidose, Llc Fulvestrant formulations
WO2013182668A1 (en) 2012-06-08 2013-12-12 F. Hoffmann-La Roche Ag Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
CN104782169B (zh) * 2013-07-08 2019-06-28 华为技术有限公司 视频播放的控制方法、设备及系统
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
WO2015033302A2 (en) * 2013-09-06 2015-03-12 Salah Uddin Ahmed Fulvestrant compositions
IL285928B2 (en) 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
US11590077B2 (en) * 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use

Similar Documents

Publication Publication Date Title
JP2019502892A5 (https=)
JP2020530380A5 (https=)
JP2021524958A5 (https=)
JP2023021979A5 (https=)
CN114650845A (zh) 抗密蛋白抗体药物偶联物及其医药用途
JP2014519662A5 (https=)
JP2013540292A5 (https=)
JP2019514354A5 (https=)
JP2013519136A5 (https=)
JP2017505048A5 (https=)
JP2020512939A5 (https=)
JP2013540293A5 (https=)
JP2019516789A5 (https=)
JP2014513356A5 (https=)
JP2015531923A5 (https=)
JP2021502362A5 (https=)
JP2013517798A5 (https=)
JP2016506003A5 (https=)
JP2020528637A5 (https=)
JP2014508098A5 (https=)
JP2019527311A5 (https=)
JP2016527801A5 (https=)
JP2018531396A5 (https=)
JP2020523490A5 (https=)
JP2020505322A5 (https=)